The future for neuro modulation and treatment for vagus nerve damage and related areas is on the horizon! You have heard this before in a hypothetical case but this appears to have gained more momentum with recent studies!!
The existing Electrome platform and Biel corporation Actipatch integration will enable real time results for physician review and dynamic treatment.
Do your due diligence!
Yes. There is a credible way to structure this as a clinically testable vagus-nerve research program using a deliverable PEMF device, BIEL/ActiPatch technology, and Electrome’s monitoring/AI platform. However, an important distinction is that ActiPatch is FDA-cleared for musculoskeletal pain, not for vagus-nerve stimulation, so a vagus application would initially be a research use rather than an established clinical indication. citeturn0search0
Proposed ActiPatch–Electrome Vagus Nerve Research Program
1. Research concept
The strongest initial study would be:
Non-invasive PEMF neuromodulation of the cervical vagus nerve with continuous physiological monitoring through the Electrome platform.
The research question would be:
Can a wearable, low-intensity pulsed electromagnetic-field device positioned over the cervical vagus region produce measurable changes in autonomic nervous-system activity, and can those changes be objectively detected and tracked through Electrome's bioelectric monitoring platform?
This is not merely theoretical. A 2025 randomized, placebo-controlled study specifically investigated PEMF applied to the neck for vagus-nerve stimulation using 6, 16 and 32 Hz stimulation. The study used a 2.5 mT peak magnetic field and reported the strongest effects at 16 Hz, including improvements in sleep quality and reductions in anxiety.
That study provides a particularly interesting starting point for an ActiPatch/Electrome research protocol.
2. How the three technologies could fit together
Component Proposed role
BIEL / ActiPatch Physical PEMF/PSWT delivery device
Electrome platform Programmable bioelectric therapy, data collection and analysis
Wearable monitoring HR, HRV, sleep, activity and autonomic response
Clinical laboratory testing CRP, IL-6, TNF-α and other inflammatory biomarkers
Clinical outcomes Pain, anxiety, sleep, fatigue and quality-of-life scores
AI/data analysis Identify responders, optimal frequency and dose-response relationships
This is especially interesting because Electrome publicly describes its platform as combining AI-enabled bioelectric therapeutics with FDA-cleared BIEL devices, while ActiPatch is already an FDA-cleared wearable PEMF/PSWT device.
Electrome and BIEL announced their partnership in March 2026, describing the combination as an AI-enabled bioelectric platform built around BIEL's FDA-cleared devices.
3. The most important research target: HRV
I would make heart-rate variability (HRV) one of the primary physiological endpoints.
The vagus nerve is heavily involved in parasympathetic regulation. Therefore, rather than simply asking patients whether they "feel better," the study should determine whether PEMF produces a measurable autonomic response.
The system could continuously monitor:
resting heart rate
SDNN
RMSSD
HF-HRV
LF-HRV
LF/HF ratio
respiratory rate
sleep duration
sleep quality
activity
blood pressure, where available
A recent 2026 clinical trial of transcutaneous vagal stimulation illustrates why objective monitoring is important: investigators used ambulatory ECG monitoring and HRV measurements rather than relying solely on subjective symptoms.
4. Proposed Phase I study
Study population
I would initially recruit approximately:
60–100 adults
The existing Electrome platform and Biel corporation Actipatch integration will enable real time results for physician review and dynamic treatment.
Do your due diligence!
Yes. There is a credible way to structure this as a clinically testable vagus-nerve research program using a deliverable PEMF device, BIEL/ActiPatch technology, and Electrome’s monitoring/AI platform. However, an important distinction is that ActiPatch is FDA-cleared for musculoskeletal pain, not for vagus-nerve stimulation, so a vagus application would initially be a research use rather than an established clinical indication. citeturn0search0
Proposed ActiPatch–Electrome Vagus Nerve Research Program
1. Research concept
The strongest initial study would be:
Non-invasive PEMF neuromodulation of the cervical vagus nerve with continuous physiological monitoring through the Electrome platform.
The research question would be:
Can a wearable, low-intensity pulsed electromagnetic-field device positioned over the cervical vagus region produce measurable changes in autonomic nervous-system activity, and can those changes be objectively detected and tracked through Electrome's bioelectric monitoring platform?
This is not merely theoretical. A 2025 randomized, placebo-controlled study specifically investigated PEMF applied to the neck for vagus-nerve stimulation using 6, 16 and 32 Hz stimulation. The study used a 2.5 mT peak magnetic field and reported the strongest effects at 16 Hz, including improvements in sleep quality and reductions in anxiety.
That study provides a particularly interesting starting point for an ActiPatch/Electrome research protocol.
2. How the three technologies could fit together
Component Proposed role
BIEL / ActiPatch Physical PEMF/PSWT delivery device
Electrome platform Programmable bioelectric therapy, data collection and analysis
Wearable monitoring HR, HRV, sleep, activity and autonomic response
Clinical laboratory testing CRP, IL-6, TNF-α and other inflammatory biomarkers
Clinical outcomes Pain, anxiety, sleep, fatigue and quality-of-life scores
AI/data analysis Identify responders, optimal frequency and dose-response relationships
This is especially interesting because Electrome publicly describes its platform as combining AI-enabled bioelectric therapeutics with FDA-cleared BIEL devices, while ActiPatch is already an FDA-cleared wearable PEMF/PSWT device.
Electrome and BIEL announced their partnership in March 2026, describing the combination as an AI-enabled bioelectric platform built around BIEL's FDA-cleared devices.
3. The most important research target: HRV
I would make heart-rate variability (HRV) one of the primary physiological endpoints.
The vagus nerve is heavily involved in parasympathetic regulation. Therefore, rather than simply asking patients whether they "feel better," the study should determine whether PEMF produces a measurable autonomic response.
The system could continuously monitor:
resting heart rate
SDNN
RMSSD
HF-HRV
LF-HRV
LF/HF ratio
respiratory rate
sleep duration
sleep quality
activity
blood pressure, where available
A recent 2026 clinical trial of transcutaneous vagal stimulation illustrates why objective monitoring is important: investigators used ambulatory ECG monitoring and HRV measurements rather than relying solely on subjective symptoms.
4. Proposed Phase I study
Study population
I would initially recruit approximately:
60–100 adults
1
